OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Antimicrobial Chemotherapy is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study	108
Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey	94
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study	86
An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London	76
Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries	70
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection	60
Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials	60
Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital	58
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19	57
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study	55
Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections	53
The changing epidemiology of carbapenemase-producingKlebsiella pneumoniaein Italy: toward polyclonal evolution with emergence of high-risk lineages	51
Oxazolidinones: mechanisms of resistance and mobile genetic elements involved	51
Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge	48
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial	44
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections	40
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid	40
Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017	39
Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019	39
Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates	39
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinicalNeisseria gonorrhoeaeisolates from 25 European countries, 2018	39
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia	37
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre	37
Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics	37
In vitrosusceptibility ofMycobacterium abscessuscomplex and feasibility of standardizing treatment regimens	36

Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile	36
Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?	35
Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications	34
IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bactera	34
Impact of an antimicrobial stewardship programme on reducing broad-spectrum antibiotic use and its effect on carbapenem-resistantAcinetobacter baumannii(CRAb) in hospitals in Jordan	34
Antimicrobial-induced horizontal transfer of antimicrobial resistance genes in bacteria: a mini-review	34
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society	33
Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)	33
Prevalence of antimicrobial resistance genes and its association with restricted antimicrobial use in food-producing animals: a systematic review and meta-analysis	33
Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing	33